(0.07%) 5 473.16 points
(0.11%) 39 157 points
(0.37%) 17 784 points
(0.10%) $80.91
(-3.66%) $2.66
(-0.77%) $2 312.80
(0.23%) $28.94
(3.64%) $1 022.30
(0.28%) $0.936
(0.69%) $10.68
(0.44%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions...
Stats | |
---|---|
今日成交量 | 156 080 |
平均成交量 | 636 846 |
市值 | 951.46M |
EPS | $-0.350 ( Q1 | 2024-05-08 ) |
下一个收益日期 | ( $-0.330 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-8.02 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0180 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-06 | Mva Investors, Llc | Sell | 63 000 | Common Stock |
2024-06-07 | Mva Investors, Llc | Sell | 77 000 | Common Stock |
2024-06-05 | Peters Malte | Buy | 37 500 | Stock Option (Right to Buy) |
2024-06-05 | Peters Malte | Buy | 6 250 | Common Stock |
2024-06-05 | Rothenberg Mace | Buy | 37 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
83.74 |
Last 94 transactions |
Buy: 13 428 373 | Sell: 769 017 |
音量 相关性
Tango Therapeutics, Inc. 相关性 - 货币/商品
Tango Therapeutics, Inc. 财务报表
Annual | 2023 |
营收: | $36.53M |
毛利润: | $34.11M (93.39 %) |
EPS: | $-1.080 |
FY | 2023 |
营收: | $36.53M |
毛利润: | $34.11M (93.39 %) |
EPS: | $-1.080 |
FY | 2022 |
营收: | $24.86M |
毛利润: | $20.83M (83.80 %) |
EPS: | $-1.230 |
FY | 2021 |
营收: | $37.04M |
毛利润: | $37.04M (100.00 %) |
EPS: | $-3.49 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。